NCT02722057View on ClinicalTrials.gov

A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients

CompletedOBSERVATIONAL
Enrollment

368

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Cystic Fibrosis
All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT02722057 - A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients | Biotech Hunter | Biotech Hunter